{"timestamp": "2026-01-18T18:48:27.983527", "question": "{}", "final_output": "Final Assessment:\nMetastatic recurrent malignancy with progressive liver, presacral, bone, and peritoneal disease and severe anemia; primary site, histology, stage, prior treatments, and current performance status remain undefined [@2022-12-29|CT][@2022-12-29|MR][@20230103|5600862].\n\nCore Treatment Strategy:\n- Urgently repeat CBC, full anemia workup, and assess for transfusion/bleeding to stabilize before biopsy/systemic therapy [@20230103|5600862].  \n- Retrieve all prior pathology/IHC and full oncologic treatment records to define primary site, histology, and treatment line (currently unknown).  \n- Arrange whole-body FDG PET/CT coordinated with image-guided biopsy of safest liver lesion for updated pathology and molecular profiling [@2022-12-29|CT].  \n- After pathology and staging clarification, reconvene MDT to choose non‑HRD‑oriented systemic category and symptom‑directed local palliation [@OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\nChange Triggers:\n- If anemia remains unstable or symptomatic despite optimization, defer invasive biopsy/systemic therapy and prioritize stabilization and supportive care.  \n- If new tissue/IHC shows non‑gynecologic or unexpected primary, shift from gynecologic pathway to site‑specific systemic and palliative strategy.", "initial_ops": {"chair": "- Advanced recurrent pelvic malignancy with progressive presacral mass, bone and liver metastases; high CA125, CA19‑9 elevation [@2022-12-29|MR][@2022-12-29|CT][@20221229|9703212].  \n- Significant anemia (Hgb 74 g/L) likely multifactorial; urgently clarify symptoms, hemodynamics, and need for transfusion before systemic therapy [@20230103|5600862].  \n- Liver and renal function currently acceptable for systemic treatment; continue to monitor closely during any therapy [@20221229|8300002].  \n- HRD/BRCA negative; consider non‑HRD–focused systemic strategies and clinical trials rather than PARP‑driven approaches [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n- Missing: current histology/stage, prior treatments, performance status, pain/neurologic status, patient goals; obtain before definitive systemic vs local palliation plan.", "oncologist": "- Diagnosis, disease stage, prior systemic treatments, and current disease status are unknown/needs update to define treatment intent and line.  \n\n- HRD-negative, BRCA1/2 wild-type; germline ATM variant; implications for PARP/DDR-targeted strategies limited [@report_id:OH2203828|2022-04-18].  \n\n- Anemia (Hgb 74 g/L, RBC 2.84×10¹²/L) may constrain myelosuppressive regimens; etiology and transfusion/iron status need update [@20230103|2023-01-03].  \n\n- Renal and hepatic function appear adequate for most systemic therapies; confirm current values and trend before new regimen [@20221229|2022-12-29].  \n\n- Tumor markers markedly elevated (CA125, CA19-9, CA15-3); need imaging and pathology update to correlate with disease burden [@20221229|2022-12-29].", "radiologist": "- Presacral pelvic mass at vaginal stump, now 53×44 mm with heterogeneous enhancement, invading adjacent peritoneum and sacrum, consistent with local recurrence. [@2022-12-29|MR]\n\n- Multiple enhancing nodules in pelvic mesentery unchanged from prior, suspicious for peritoneal metastatic disease. [@2022-12-29|MR]\n\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis. [@2022-12-29|MR]\n\n- Liver with multiple metastatic nodules, increased number and size versus October 2022; coexisting stable hepatic cysts. [@2022-12-29|CT]\n\n- Splenic patchy low-density area possibly infarct; recommend correlation with symptoms and follow-up imaging. [@2022-12-29|CT]", "pathologist": "- No histology or IHC reports are available; tumor type, primary site, and grade remain completely undefined (needs surgical pathology report).  \n- Germline ATM exon8 c.A947G p.Y316C variant reported; clinical significance for this case not specified [@OH2203828|2022-04-18].  \n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 show no pathogenic variants detected [@OH2203828|2022-04-18].  \n- Somatic tumor sequencing results are not documented; updated tumor NGS/HRR panel from most recent tissue, if done, is needed.  \n- Correlation of this germline panel with a specific malignancy is impossible without updated pathology diagnosis and staging information.", "nuclear": "- No PET/CT available; metabolic characterization of liver, pelvic, and bone lesions currently impossible—FDG PET/CT needed for staging update.  \n\n- CT shows multiple enlarging liver low-density nodules, radiologically consistent with progressive hepatic metastases, not yet metabolically confirmed [@2022-12-29|CT].  \n\n- Pelvic MRI indicates enlarging presacral mass with peritoneal and sacral involvement, suspicious for local recurrence and invasion [@2022-12-29|MR].  \n\n- MRI also shows new enhancing right iliac bone lesion and mesenteric nodules, suspicious for osseous and peritoneal metastases [@2022-12-29|MR].  \n\n- Need current whole-body FDG PET/CT to assess metabolic activity, confirm recurrence extent, and potentially upstage with additional distant lesions."}, "merged_summary": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.", "final_round_ops": {"Round 1": {"chair": "- Urgently repeat labs and assess for transfusion/bleeding causes to stabilize severe anemia before any systemic therapy [@20230103|5600862].  \n- Retrieve and review all prior pathology/IHC and oncology treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \n- Perform comprehensive clinical assessment (ECOG, pain, neurologic deficits, other symptoms, goals/preferences) to guide intent and balance systemic versus local palliation (currently unknown).  \n- Arrange whole-body FDG PET/CT, coordinated with radiology for possible image-guided biopsy, ensuring it does not delay anemia management (prior PET unknown).  \n- After data updated, re-discuss in MDT to select appropriate non‑HRD systemic strategy and prioritize palliative RT or other local measures [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].", "oncologist": "- Urgently repeat CBC, iron studies, hemolysis markers, coagulation; arrange transfusion/optimization for severe anemia before systemic therapy [@20230103|2023-01-03].  \n\n- Retrieve and review all prior pathology/IHC and systemic treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \n\n- Obtain updated ECOG performance status, detailed symptom assessment (pain, neurologic deficits, bleeding), and goals of care to guide intensity of systemic vs palliative strategies (unknown).  \n\n- Coordinate whole-body FDG PET/CT with image-guided biopsy of a safe lesion (e.g., liver or presacral) to refine staging and secure tissue diagnosis (no PET or recent biopsy available).  \n\n- After above, re-discuss in MDT to select appropriate non‑HRD systemic treatment category and prioritize local palliative measures (e.g., sacral/bone RT) as needed [@report_id:OH2203828|2022-04-18].", "radiologist": "- Urgently retrieve and upload all prior surgical/biopsy pathology and IHC to define primary site and histology (currently unknown).  \n\n- Obtain updated labs (CBC, iron studies, hemolysis, renal, hepatic, coagulation) and assess need for transfusion; last Hgb 74 g/L [@lab|unknown].  \n\n- Arrange whole-body FDG PET/CT to refine current staging and metabolic burden; no prior PET/CT available [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Coordinate PET/CT timing with potential image-guided biopsy of a safe, accessible lesion (e.g., liver or presacral mass) for diagnosis.  \n\n- Re-discuss in MDT after pathology retrieval, PET/CT, and anemia optimization to balance systemic options versus symptom-directed local palliation.", "pathologist": "- Primary site, histologic type, grade, and staging remain unknown; urgently retrieve all prior surgical/biopsy and IHC reports (unknown/needs update).  \n- No tumor histology/IHC from current lesions is available; consider image-guided biopsy of a representative site after records review (unknown/needs update).  \n- Only documented molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; somatic NGS on tumor unknown [@OH2203828|2022-04-18].  \n- Recommend deferring any pathology-based treatment stratification labels (e.g., “ovarian,” “GI,” “gynecologic”) until full pathology and IHC are obtained (unknown/needs update).  \n- Once prior and/or new tissue is available, perform integrated histology, IHC, and, if feasible, tumor NGS to clarify primary and lineage (unknown/needs update).", "nuclear": "- Arrange whole-body FDG PET/CT to define metabolic burden, detect occult metastases, and better stage liver, presacral, bone, peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \n- Coordinate PET/CT timing with any planned image-guided biopsy so staging and tissue acquisition occur in a single diagnostic pathway.  \n- Ensure PET/CT scheduling does not delay urgent anemia evaluation/optimization and symptom-directed local measures (e.g., sacral/bone palliation) as determined by other teams.  \n- Use PET/CT to help distinguish dominant pelvic versus hepatic/bone disease compartments, informing prioritization of systemic versus local palliative strategies.  \n- Confirm whether any prior PET/CT exists; if so, compare with new PET to assess metabolic progression and treatment response potential (if available)."}, "Round 2": {"chair": "- Stabilize anemia urgently with repeat CBC and workup before invasive biopsy or systemic therapy decisions [@20230103|5600862].  \n- Retrieve and review all prior pathology/IHC and treatment records to define primary site, histology, and treatment line (currently unknown).  \n- Proceed with whole-body FDG PET/CT, coordinated so a safe, accessible liver lesion can be biopsied in the same care episode [@2022-12-29|CT].  \n- After new pathology and staging, re‑convene MDT to choose appropriate non‑HRD systemic strategy and local palliation options [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n- Assess current performance status, pain/neurologic symptoms, bleeding, and patient goals to prioritize timing of RT versus systemic therapy (all currently unknown).", "oncologist": "- Repeat CBC, iron studies, hemolysis markers, renal/hepatic function, and coagulation; urgently assess transfusion/bleeding risk for Hgb 74 g/L [@20230103|2023-01-03].  \n\n- Retrieve all prior pathology/IHC and complete oncologic treatment history to define primary site, histology, stage, and systemic line (currently unknown).  \n\n- Perform focused clinical assessment (ECOG, pain/neurologic deficits, bleeding, constitutional symptoms, goals) to balance systemic versus palliative‑local treatment intensity (unknown).  \n\n- Coordinate whole-body FDG PET/CT with image‑guided liver lesion biopsy as preferred target, provided this does not delay anemia optimization (prior PET/biopsy details unknown).  \n\n- After diagnostic clarification, re-discuss in MDT to choose appropriate non‑HRD systemic treatment category and prioritize symptom‑directed local measures (e.g., sacral/iliac RT) [@OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].", "radiologist": "- Presacral pelvic mass invading sacrum/peritoneum with stable-to-progressive appearance on serial MR, suggesting locally advanced recurrent disease [@2022-10-24|MR][@2022-12-29|MR].  \n\n- Progressive liver metastases: multiple low-density hepatic nodules increased in number/size, largest ~17×14 mm [@2022-12-29|CT].  \n\n- New enhancing right iliac bone lesion and multiple pelvic mesenteric nodules, consistent with osseous and peritoneal metastases [@2022-12-29|MR].  \n\n- Possible splenic infarct manifested as patchy low-density splenic area, requiring clinical correlation and follow-up imaging [@2022-12-29|CT].  \n\n- No biliary obstruction or ascites; hepatic vasculature and bile ducts remain patent despite metastatic burden [@2022-12-29|CT].", "pathologist": "- Primary site, histology, grade, and stage remain undefined; urgently obtain and upload all historical pathology and IHC reports (unknown/needs update).  \n- No tissue diagnosis from current metastatic sites is available; plan image‑guided liver lesion biopsy coordinated with PET/CT for staging (unknown/needs update).  \n- Only confirmed molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; tumor somatic NGS unknown [@OH2203828|2022-04-18].  \n- Do not assign organ‑specific labels (gynecologic vs non‑gynecologic) or subtype‑specific treatment pathways until integrated histology/IHC and molecular results are available (unknown/needs update).  \n- Once tissue obtained, perform comprehensive morphology, IHC panel, and, if feasible, broad NGS to clarify lineage and potential biomarkers (unknown/needs update).", "nuclear": "- Schedule whole-body FDG PET/CT to characterize metabolic activity and full extent of liver, presacral, bone, and peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \n- Coordinate PET/CT with planned image-guided biopsy of the safest, metabolically active liver lesion to maximize diagnostic and molecular yield [@2022-12-29|CT].  \n- Ensure PET/CT and biopsy timing do not delay urgent anemia evaluation, optimization, or necessary rapid palliative interventions (e.g., for sacral/iliac pain).  \n- Use PET/CT to assess for additional symptomatic or impending-complication sites (e.g., spine, weight-bearing bone, bowel/ureter involvement) to inform local palliation.  \n- Compare upcoming PET/CT with any future imaging to monitor metabolic response or progression once a treatment strategy is defined (if pursued)."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before proposing any regimen, anemia (Hb 74 g/L) and performance status must be urgently clarified and stabilized, and prior systemic/locoregional treatments retrieved to define true line of therapy and intent.", "radiologist": "Given sacral invasion, iliac bone lesion, and progressive liver disease, please comment on imminent fracture/neurologic risk and whether targeted palliative RT fields are technically feasible now versus after systemic therapy.", "pathologist": "We need definitive pathology (primary site, histologic subtype/grade, IHC panel) from prior surgery/biopsies; if inconclusive or inaccessible, advise on the safest current biopsy site for confirmation.", "nuclear": "Please advise whether FDG PET/CT would meaningfully refine staging and guide selection/priority of systemic versus local palliative approaches in this disseminated setting."}, "oncologist": {"chair": "Before deciding on systemic therapy, we still lack definitive primary histology, full prior treatment history, and current ECOG; could we prioritize retrieving outside oncology/pathology records and documenting performance status today?", "oncologist": null, "radiologist": "Given the enlarging presacral mass with sacral invasion and new right iliac bone lesion, can you comment on feasibility and urgency of image‑guided biopsy targets and whether any features suggest a non‑gynecologic primary?", "pathologist": "Do we have any prior pathology blocks or reports (including IHC) that clarify primary site and subtype of this pelvic malignancy, or should we plan a new biopsy of the presacral or liver lesion?", "nuclear": "Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning?"}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging.", "radiologist": "Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Systemic therapy planning should be deferred until we obtain prior pathology/oncology records and stabilize the severe anemia with updated labs and transfusion assessment.", "radiologist": "Please coordinate with nuclear medicine to sequence baseline whole-body FDG PET/CT alongside any planned future MRI/CT, avoiding redundant imaging and excessive contrast load.", "pathologist": "Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe.", "nuclear": "Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed."}, "oncologist": {"chair": "Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen?", "oncologist": null, "radiologist": "In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?", "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT.", "radiologist": null, "pathologist": null, "nuclear": "When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion."}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently.", "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": "Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.", "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Advanced recurrent pelvic malignancy with progressive presacral mass, bone and liver metastases; high CA125, CA19‑9 elevation [@2022-12-29|MR][@2022-12-29|CT][@20221229|9703212].  \n- Significant anemia (Hgb 74 g/L) likely multifactorial; urgently clarify symptoms, hemodynamics, and need for transfusion before systemic therapy [@20230103|5600862].  \n- Liver and renal function currently acceptable for systemic treatment; continue to monitor closely during any therapy [@20221229|8300002].  \n- HRD/BRCA negative; consider non‑HRD–focused systemic strategies and clinical trials rather than PARP‑driven approaches [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n- Missing: current histology/stage, prior treatments, performance status, pain/neurologic status, patient goals; obtain before definitive systemic vs local palliation plan.", "timestamp": "2026-01-18T18:45:13.491249"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before proposing any regimen, anemia (Hb 74 g/L) and performance status must be urgently clarified and stabilized, and prior systemic/locoregional treatments retrieved to define true line of therapy and intent.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Given sacral invasion, iliac bone lesion, and progressive liver disease, please comment on imminent fracture/neurologic risk and whether targeted palliative RT fields are technically feasible now versus after systemic therapy.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"We need definitive pathology (primary site, histologic subtype/grade, IHC panel) from prior surgery/biopsies; if inconclusive or inaccessible, advise on the safest current biopsy site for confirmation.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Please advise whether FDG PET/CT would meaningfully refine staging and guide selection/priority of systemic versus local palliative approaches in this disseminated setting.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:45:38.255934"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Systemic therapy planning should be deferred until we obtain prior pathology/oncology records and stabilize the severe anemia with updated labs and transfusion assessment.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please coordinate with nuclear medicine to sequence baseline whole-body FDG PET/CT alongside any planned future MRI/CT, avoiding redundant imaging and excessive contrast load.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T18:45:49.269628"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently repeat labs and assess for transfusion/bleeding causes to stabilize severe anemia before any systemic therapy [@20230103|5600862].  \n- Retrieve and review all prior pathology/IHC and oncology treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \n- Perform comprehensive clinical assessment (ECOG, pain, neurologic deficits, other symptoms, goals/preferences) to guide intent and balance systemic versus local palliation (currently unknown).  \n- Arrange whole-body FDG PET/CT, coordinated with radiology for possible image-guided biopsy, ensuring it does not delay anemia management (prior PET unknown).  \n- After data updated, re-discuss in MDT to select appropriate non‑HRD systemic strategy and prioritize palliative RT or other local measures [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].", "timestamp": "2026-01-18T18:45:58.541972"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:46:44.327659"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently.\",\"why\":\"missing-critical\"}]}", "timestamp": "2026-01-18T18:47:01.860596"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Stabilize anemia urgently with repeat CBC and workup before invasive biopsy or systemic therapy decisions [@20230103|5600862].  \n- Retrieve and review all prior pathology/IHC and treatment records to define primary site, histology, and treatment line (currently unknown).  \n- Proceed with whole-body FDG PET/CT, coordinated so a safe, accessible liver lesion can be biopsied in the same care episode [@2022-12-29|CT].  \n- After new pathology and staging, re‑convene MDT to choose appropriate non‑HRD systemic strategy and local palliation options [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n- Assess current performance status, pain/neurologic symptoms, bleeding, and patient goals to prioritize timing of RT versus systemic therapy (all currently unknown).", "timestamp": "2026-01-18T18:47:51.851852"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id|page] or [@pubmed:PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Urgently repeat labs and assess for transfusion/bleeding causes to stabilize severe anemia before any systemic therapy [@20230103|5600862].  \\n- Retrieve and review all prior pathology/IHC and oncology treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \\n- Perform comprehensive clinical assessment (ECOG, pain, neurologic deficits, other symptoms, goals/preferences) to guide intent and balance systemic versus local palliation (currently unknown).  \\n- Arrange whole-body FDG PET/CT, coordinated with radiology for possible image-guided biopsy, ensuring it does not delay anemia management (prior PET unknown).  \\n- After data updated, re-discuss in MDT to select appropriate non‑HRD systemic strategy and prioritize palliative RT or other local measures [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].\",\n    \"oncologist\": \"- Urgently repeat CBC, iron studies, hemolysis markers, coagulation; arrange transfusion/optimization for severe anemia before systemic therapy [@20230103|2023-01-03].  \\n\\n- Retrieve and review all prior pathology/IHC and systemic treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \\n\\n- Obtain updated ECOG performance status, detailed symptom assessment (pain, neurologic deficits, bleeding), and goals of care to guide intensity of systemic vs palliative strategies (unknown).  \\n\\n- Coordinate whole-body FDG PET/CT with image-guided biopsy of a safe lesion (e.g., liver or presacral) to refine staging and secure tissue diagnosis (no PET or recent biopsy available).  \\n\\n- After above, re-discuss in MDT to select appropriate non‑HRD systemic treatment category and prioritize local palliative measures (e.g., sacral/bone RT) as needed [@report_id:OH2203828|2022-04-18].\",\n    \"radiologist\": \"- Urgently retrieve and upload all prior surgical/biopsy pathology and IHC to define primary site and histology (currently unknown).  \\n\\n- Obtain updated labs (CBC, iron studies, hemolysis, renal, hepatic, coagulation) and assess need for transfusion; last Hgb 74 g/L [@lab|unknown].  \\n\\n- Arrange whole-body FDG PET/CT to refine current staging and metabolic burden; no prior PET/CT available [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Coordinate PET/CT timing with potential image-guided biopsy of a safe, accessible lesion (e.g., liver or presacral mass) for diagnosis.  \\n\\n- Re-discuss in MDT after pathology retrieval, PET/CT, and anemia optimization to balance systemic options versus symptom-directed local palliation.\",\n    \"pathologist\": \"- Primary site, histologic type, grade, and staging remain unknown; urgently retrieve all prior surgical/biopsy and IHC reports (unknown/needs update).  \\n- No tumor histology/IHC from current lesions is available; consider image-guided biopsy of a representative site after records review (unknown/needs update).  \\n- Only documented molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; somatic NGS on tumor unknown [@OH2203828|2022-04-18].  \\n- Recommend deferring any pathology-based treatment stratification labels (e.g., “ovarian,” “GI,” “gynecologic”) until full pathology and IHC are obtained (unknown/needs update).  \\n- Once prior and/or new tissue is available, perform integrated histology, IHC, and, if feasible, tumor NGS to clarify primary and lineage (unknown/needs update).\",\n    \"nuclear\": \"- Arrange whole-body FDG PET/CT to define metabolic burden, detect occult metastases, and better stage liver, presacral, bone, peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \\n- Coordinate PET/CT timing with any planned image-guided biopsy so staging and tissue acquisition occur in a single diagnostic pathway.  \\n- Ensure PET/CT scheduling does not delay urgent anemia evaluation/optimization and symptom-directed local measures (e.g., sacral/bone palliation) as determined by other teams.  \\n- Use PET/CT to help distinguish dominant pelvic versus hepatic/bone disease compartments, informing prioritization of systemic versus local palliative strategies.  \\n- Confirm whether any prior PET/CT exists; if so, compare with new PET to assess metabolic progression and treatment response potential (if available).\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Stabilize anemia urgently with repeat CBC and workup before invasive biopsy or systemic therapy decisions [@20230103|5600862].  \\n- Retrieve and review all prior pathology/IHC and treatment records to define primary site, histology, and treatment line (currently unknown).  \\n- Proceed with whole-body FDG PET/CT, coordinated so a safe, accessible liver lesion can be biopsied in the same care episode [@2022-12-29|CT].  \\n- After new pathology and staging, re‑convene MDT to choose appropriate non‑HRD systemic strategy and local palliation options [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \\n- Assess current performance status, pain/neurologic symptoms, bleeding, and patient goals to prioritize timing of RT versus systemic therapy (all currently unknown).\",\n    \"oncologist\": \"- Repeat CBC, iron studies, hemolysis markers, renal/hepatic function, and coagulation; urgently assess transfusion/bleeding risk for Hgb 74 g/L [@20230103|2023-01-03].  \\n\\n- Retrieve all prior pathology/IHC and complete oncologic treatment history to define primary site, histology, stage, and systemic line (currently unknown).  \\n\\n- Perform focused clinical assessment (ECOG, pain/neurologic deficits, bleeding, constitutional symptoms, goals) to balance systemic versus palliative‑local treatment intensity (unknown).  \\n\\n- Coordinate whole-body FDG PET/CT with image‑guided liver lesion biopsy as preferred target, provided this does not delay anemia optimization (prior PET/biopsy details unknown).  \\n\\n- After diagnostic clarification, re-discuss in MDT to choose appropriate non‑HRD systemic treatment category and prioritize symptom‑directed local measures (e.g., sacral/iliac RT) [@OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].\",\n    \"radiologist\": \"- Presacral pelvic mass invading sacrum/peritoneum with stable-to-progressive appearance on serial MR, suggesting locally advanced recurrent disease [@2022-10-24|MR][@2022-12-29|MR].  \\n\\n- Progressive liver metastases: multiple low-density hepatic nodules increased in number/size, largest ~17×14 mm [@2022-12-29|CT].  \\n\\n- New enhancing right iliac bone lesion and multiple pelvic mesenteric nodules, consistent with osseous and peritoneal metastases [@2022-12-29|MR].  \\n\\n- Possible splenic infarct manifested as patchy low-density splenic area, requiring clinical correlation and follow-up imaging [@2022-12-29|CT].  \\n\\n- No biliary obstruction or ascites; hepatic vasculature and bile ducts remain patent despite metastatic burden [@2022-12-29|CT].\",\n    \"pathologist\": \"- Primary site, histology, grade, and stage remain undefined; urgently obtain and upload all historical pathology and IHC reports (unknown/needs update).  \\n- No tissue diagnosis from current metastatic sites is available; plan image‑guided liver lesion biopsy coordinated with PET/CT for staging (unknown/needs update).  \\n- Only confirmed molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; tumor somatic NGS unknown [@OH2203828|2022-04-18].  \\n- Do not assign organ‑specific labels (gynecologic vs non‑gynecologic) or subtype‑specific treatment pathways until integrated histology/IHC and molecular results are available (unknown/needs update).  \\n- Once tissue obtained, perform comprehensive morphology, IHC panel, and, if feasible, broad NGS to clarify lineage and potential biomarkers (unknown/needs update).\",\n    \"nuclear\": \"- Schedule whole-body FDG PET/CT to characterize metabolic activity and full extent of liver, presacral, bone, and peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \\n- Coordinate PET/CT with planned image-guided biopsy of the safest, metabolically active liver lesion to maximize diagnostic and molecular yield [@2022-12-29|CT].  \\n- Ensure PET/CT and biopsy timing do not delay urgent anemia evaluation, optimization, or necessary rapid palliative interventions (e.g., for sacral/iliac pain).  \\n- Use PET/CT to assess for additional symptomatic or impending-complication sites (e.g., spine, weight-bearing bone, bowel/ureter involvement) to inform local palliation.  \\n- Compare upcoming PET/CT with any future imaging to monitor metabolic response or progression once a treatment strategy is defined (if pursued).\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nMetastatic recurrent malignancy with progressive liver, presacral, bone, and peritoneal disease and severe anemia; primary site, histology, stage, prior treatments, and current performance status remain undefined [@2022-12-29|CT][@2022-12-29|MR][@20230103|5600862].\n\nCore Treatment Strategy:\n- Urgently repeat CBC, full anemia workup, and assess for transfusion/bleeding to stabilize before biopsy/systemic therapy [@20230103|5600862].  \n- Retrieve all prior pathology/IHC and full oncologic treatment records to define primary site, histology, and treatment line (currently unknown).  \n- Arrange whole-body FDG PET/CT coordinated with image-guided biopsy of safest liver lesion for updated pathology and molecular profiling [@2022-12-29|CT].  \n- After pathology and staging clarification, reconvene MDT to choose non‑HRD‑oriented systemic category and symptom‑directed local palliation [@OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\nChange Triggers:\n- If anemia remains unstable or symptomatic despite optimization, defer invasive biopsy/systemic therapy and prioritize stabilization and supportive care.  \n- If new tissue/IHC shows non‑gynecologic or unexpected primary, shift from gynecologic pathway to site‑specific systemic and palliative strategy.", "timestamp": "2026-01-18T18:48:27.983291"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Diagnosis, disease stage, prior systemic treatments, and current disease status are unknown/needs update to define treatment intent and line.  \n\n- HRD-negative, BRCA1/2 wild-type; germline ATM variant; implications for PARP/DDR-targeted strategies limited [@report_id:OH2203828|2022-04-18].  \n\n- Anemia (Hgb 74 g/L, RBC 2.84×10¹²/L) may constrain myelosuppressive regimens; etiology and transfusion/iron status need update [@20230103|2023-01-03].  \n\n- Renal and hepatic function appear adequate for most systemic therapies; confirm current values and trend before new regimen [@20221229|2022-12-29].  \n\n- Tumor markers markedly elevated (CA125, CA19-9, CA15-3); need imaging and pathology update to correlate with disease burden [@20221229|2022-12-29].", "timestamp": "2026-01-18T18:45:16.644671"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Before deciding on systemic therapy, we still lack definitive primary histology, full prior treatment history, and current ECOG; could we prioritize retrieving outside oncology/pathology records and documenting performance status today?\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Do we have any prior pathology blocks or reports (including IHC) that clarify primary site and subtype of this pelvic malignancy, or should we plan a new biopsy of the presacral or liver lesion?\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Given the enlarging presacral mass with sacral invasion and new right iliac bone lesion, can you comment on feasibility and urgency of image‑guided biopsy targets and whether any features suggest a non‑gynecologic primary?\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning?\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:45:41.372748"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen?\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:45:51.537748"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently repeat CBC, iron studies, hemolysis markers, coagulation; arrange transfusion/optimization for severe anemia before systemic therapy [@20230103|2023-01-03].  \n\n- Retrieve and review all prior pathology/IHC and systemic treatment records to define primary site, histology, stage, and treatment line (currently unknown).  \n\n- Obtain updated ECOG performance status, detailed symptom assessment (pain, neurologic deficits, bleeding), and goals of care to guide intensity of systemic vs palliative strategies (unknown).  \n\n- Coordinate whole-body FDG PET/CT with image-guided biopsy of a safe lesion (e.g., liver or presacral) to refine staging and secure tissue diagnosis (no PET or recent biopsy available).  \n\n- After above, re-discuss in MDT to select appropriate non‑HRD systemic treatment category and prioritize local palliative measures (e.g., sacral/bone RT) as needed [@report_id:OH2203828|2022-04-18].", "timestamp": "2026-01-18T18:46:01.516706"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:46:49.296316"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:47:19.807311"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Repeat CBC, iron studies, hemolysis markers, renal/hepatic function, and coagulation; urgently assess transfusion/bleeding risk for Hgb 74 g/L [@20230103|2023-01-03].  \n\n- Retrieve all prior pathology/IHC and complete oncologic treatment history to define primary site, histology, stage, and systemic line (currently unknown).  \n\n- Perform focused clinical assessment (ECOG, pain/neurologic deficits, bleeding, constitutional symptoms, goals) to balance systemic versus palliative‑local treatment intensity (unknown).  \n\n- Coordinate whole-body FDG PET/CT with image‑guided liver lesion biopsy as preferred target, provided this does not delay anemia optimization (prior PET/biopsy details unknown).  \n\n- After diagnostic clarification, re-discuss in MDT to choose appropriate non‑HRD systemic treatment category and prioritize symptom‑directed local measures (e.g., sacral/iliac RT) [@OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|14].", "timestamp": "2026-01-18T18:47:54.858437"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Presacral pelvic mass at vaginal stump, now 53×44 mm with heterogeneous enhancement, invading adjacent peritoneum and sacrum, consistent with local recurrence. [@2022-12-29|MR]\n\n- Multiple enhancing nodules in pelvic mesentery unchanged from prior, suspicious for peritoneal metastatic disease. [@2022-12-29|MR]\n\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis. [@2022-12-29|MR]\n\n- Liver with multiple metastatic nodules, increased number and size versus October 2022; coexisting stable hepatic cysts. [@2022-12-29|CT]\n\n- Splenic patchy low-density area possibly infarct; recommend correlation with symptoms and follow-up imaging. [@2022-12-29|CT]", "timestamp": "2026-01-18T18:45:19.383138"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:45:42.719192"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:45:52.935517"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently retrieve and upload all prior surgical/biopsy pathology and IHC to define primary site and histology (currently unknown).  \n\n- Obtain updated labs (CBC, iron studies, hemolysis, renal, hepatic, coagulation) and assess need for transfusion; last Hgb 74 g/L [@lab|unknown].  \n\n- Arrange whole-body FDG PET/CT to refine current staging and metabolic burden; no prior PET/CT available [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Coordinate PET/CT timing with potential image-guided biopsy of a safe, accessible lesion (e.g., liver or presacral mass) for diagnosis.  \n\n- Re-discuss in MDT after pathology retrieval, PET/CT, and anemia optimization to balance systemic options versus symptom-directed local palliation.", "timestamp": "2026-01-18T18:46:16.802544"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:46:53.090842"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:47:22.802685"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Presacral pelvic mass invading sacrum/peritoneum with stable-to-progressive appearance on serial MR, suggesting locally advanced recurrent disease [@2022-10-24|MR][@2022-12-29|MR].  \n\n- Progressive liver metastases: multiple low-density hepatic nodules increased in number/size, largest ~17×14 mm [@2022-12-29|CT].  \n\n- New enhancing right iliac bone lesion and multiple pelvic mesenteric nodules, consistent with osseous and peritoneal metastases [@2022-12-29|MR].  \n\n- Possible splenic infarct manifested as patchy low-density splenic area, requiring clinical correlation and follow-up imaging [@2022-12-29|CT].  \n\n- No biliary obstruction or ascites; hepatic vasculature and bile ducts remain patent despite metastatic burden [@2022-12-29|CT].", "timestamp": "2026-01-18T18:47:58.138642"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No histology or IHC reports are available; tumor type, primary site, and grade remain completely undefined (needs surgical pathology report).  \n- Germline ATM exon8 c.A947G p.Y316C variant reported; clinical significance for this case not specified [@OH2203828|2022-04-18].  \n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 show no pathogenic variants detected [@OH2203828|2022-04-18].  \n- Somatic tumor sequencing results are not documented; updated tumor NGS/HRR panel from most recent tissue, if done, is needed.  \n- Correlation of this germline panel with a specific malignancy is impossible without updated pathology diagnosis and staging information.", "timestamp": "2026-01-18T18:45:21.993604"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:45:44.496702"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:45:54.206973"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Primary site, histologic type, grade, and staging remain unknown; urgently retrieve all prior surgical/biopsy and IHC reports (unknown/needs update).  \n- No tumor histology/IHC from current lesions is available; consider image-guided biopsy of a representative site after records review (unknown/needs update).  \n- Only documented molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; somatic NGS on tumor unknown [@OH2203828|2022-04-18].  \n- Recommend deferring any pathology-based treatment stratification labels (e.g., “ovarian,” “GI,” “gynecologic”) until full pathology and IHC are obtained (unknown/needs update).  \n- Once prior and/or new tissue is available, perform integrated histology, IHC, and, if feasible, tumor NGS to clarify primary and lineage (unknown/needs update).", "timestamp": "2026-01-18T18:46:23.460705"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:46:54.562919"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:47:42.082451"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Primary site, histology, grade, and stage remain undefined; urgently obtain and upload all historical pathology and IHC reports (unknown/needs update).  \n- No tissue diagnosis from current metastatic sites is available; plan image‑guided liver lesion biopsy coordinated with PET/CT for staging (unknown/needs update).  \n- Only confirmed molecular data: germline ATM p.Y316C, HRD‑negative, BRCA1/2 wild-type; tumor somatic NGS unknown [@OH2203828|2022-04-18].  \n- Do not assign organ‑specific labels (gynecologic vs non‑gynecologic) or subtype‑specific treatment pathways until integrated histology/IHC and molecular results are available (unknown/needs update).  \n- Once tissue obtained, perform comprehensive morphology, IHC panel, and, if feasible, broad NGS to clarify lineage and potential biomarkers (unknown/needs update).", "timestamp": "2026-01-18T18:48:03.474400"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No PET/CT available; metabolic characterization of liver, pelvic, and bone lesions currently impossible—FDG PET/CT needed for staging update.  \n\n- CT shows multiple enlarging liver low-density nodules, radiologically consistent with progressive hepatic metastases, not yet metabolically confirmed [@2022-12-29|CT].  \n\n- Pelvic MRI indicates enlarging presacral mass with peritoneal and sacral involvement, suspicious for local recurrence and invasion [@2022-12-29|MR].  \n\n- MRI also shows new enhancing right iliac bone lesion and mesenteric nodules, suspicious for osseous and peritoneal metastases [@2022-12-29|MR].  \n\n- Need current whole-body FDG PET/CT to assess metabolic activity, confirm recurrence extent, and potentially upstage with additional distant lesions.", "timestamp": "2026-01-18T18:45:24.834317"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:45:46.635331"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:45:55.548548"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Arrange whole-body FDG PET/CT to define metabolic burden, detect occult metastases, and better stage liver, presacral, bone, peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \n- Coordinate PET/CT timing with any planned image-guided biopsy so staging and tissue acquisition occur in a single diagnostic pathway.  \n- Ensure PET/CT scheduling does not delay urgent anemia evaluation/optimization and symptom-directed local measures (e.g., sacral/bone palliation) as determined by other teams.  \n- Use PET/CT to help distinguish dominant pelvic versus hepatic/bone disease compartments, informing prioritization of systemic versus local palliative strategies.  \n- Confirm whether any prior PET/CT exists; if so, compare with new PET to assess metabolic progression and treatment response potential (if available).", "timestamp": "2026-01-18T18:46:37.613516"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:46:58.535213"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:47:45.096538"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).\n[R2T1 DELTA] radiologist->oncologist(missing): From imaging, liver lesions appear suitable for ultrasound/CT-guided biopsy; please indicate preferred target so we can plan alongside PET/CT. | radiologist->nuclear(missing): When scheduling PET/CT, please coordinate with us to allow same-day or sequential image-guided biopsy of a chosen lesion.\n[R2T2 DELTA] chair->oncologist(unspecified): Please specify whether liver versus pelvic lesion biopsy is preferred, balancing diagnostic yield and procedural risk in this anemic patient, so radiology/nuclear can plan with PET/CT efficiently. | oncologist->radiologist(missing): Given the need for broad molecular profiling, I’d favor a liver lesion as the primary biopsy target; please select the safest, most accessible site and coordinate with nuclear for PET/CT‑linked scheduling.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Schedule whole-body FDG PET/CT to characterize metabolic activity and full extent of liver, presacral, bone, and peritoneal disease [@2022-12-29|CT][@2022-12-29|MR].  \n- Coordinate PET/CT with planned image-guided biopsy of the safest, metabolically active liver lesion to maximize diagnostic and molecular yield [@2022-12-29|CT].  \n- Ensure PET/CT and biopsy timing do not delay urgent anemia evaluation, optimization, or necessary rapid palliative interventions (e.g., for sacral/iliac pain).  \n- Use PET/CT to assess for additional symptomatic or impending-complication sites (e.g., spine, weight-bearing bone, bowel/ureter involvement) to inform local palliation.  \n- Compare upcoming PET/CT with any future imaging to monitor metabolic response or progression once a treatment strategy is defined (if pursued).", "timestamp": "2026-01-18T18:48:24.320909"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Advanced recurrent pelvic malignancy with progressive presacral mass, bone and liver metastases; high CA125, CA19‑9 elevation [@2022-12-29|MR][@2022-12-29|CT][@20221229|9703212].  \\n- Significant anemia (Hgb 74 g/L) likely multifactorial; urgently clarify symptoms, hemodynamics, and need for transfusion before systemic therapy [@20230103|5600862].  \\n- Liver and renal function currently acceptable for systemic treatment; continue to monitor closely during any therapy [@20221229|8300002].  \\n- HRD/BRCA negative; consider non‑HRD–focused systemic strategies and clinical trials rather than PARP‑driven approaches [@OH2203828][@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \\n- Missing: current histology/stage, prior treatments, performance status, pain/neurologic status, patient goals; obtain before definitive systemic vs local palliation plan.\",\"oncologist\":\"- Diagnosis, disease stage, prior systemic treatments, and current disease status are unknown/needs update to define treatment intent and line.  \\n\\n- HRD-negative, BRCA1/2 wild-type; germline ATM variant; implications for PARP/DDR-targeted strategies limited [@report_id:OH2203828|2022-04-18].  \\n\\n- Anemia (Hgb 74 g/L, RBC 2.84×10¹²/L) may constrain myelosuppressive regimens; etiology and transfusion/iron status need update [@20230103|2023-01-03].  \\n\\n- Renal and hepatic function appear adequate for most systemic therapies; confirm current values and trend before new regimen [@20221229|2022-12-29].  \\n\\n- Tumor markers markedly elevated (CA125, CA19-9, CA15-3); need imaging and pathology update to correlate with disease burden [@20221229|2022-12-29].\",\"radiologist\":\"- Presacral pelvic mass at vaginal stump, now 53×44 mm with heterogeneous enhancement, invading adjacent peritoneum and sacrum, consistent with local recurrence. [@2022-12-29|MR]\\n\\n- Multiple enhancing nodules in pelvic mesentery unchanged from prior, suspicious for peritoneal metastatic disease. [@2022-12-29|MR]\\n\\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis. [@2022-12-29|MR]\\n\\n- Liver with multiple metastatic nodules, increased number and size versus October 2022; coexisting stable hepatic cysts. [@2022-12-29|CT]\\n\\n- Splenic patchy low-density area possibly infarct; recommend correlation with symptoms and follow-up imaging. [@2022-12-29|CT]\",\"pathologist\":\"- No histology or IHC reports are available; tumor type, primary site, and grade remain completely undefined (needs surgical pathology report).  \\n- Germline ATM exon8 c.A947G p.Y316C variant reported; clinical significance for this case not specified [@OH2203828|2022-04-18].  \\n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 show no pathogenic variants detected [@OH2203828|2022-04-18].  \\n- Somatic tumor sequencing results are not documented; updated tumor NGS/HRR panel from most recent tissue, if done, is needed.  \\n- Correlation of this germline panel with a specific malignancy is impossible without updated pathology diagnosis and staging information.\",\"nuclear\":\"- No PET/CT available; metabolic characterization of liver, pelvic, and bone lesions currently impossible—FDG PET/CT needed for staging update.  \\n\\n- CT shows multiple enlarging liver low-density nodules, radiologically consistent with progressive hepatic metastases, not yet metabolically confirmed [@2022-12-29|CT].  \\n\\n- Pelvic MRI indicates enlarging presacral mass with peritoneal and sacral involvement, suspicious for local recurrence and invasion [@2022-12-29|MR].  \\n\\n- MRI also shows new enhancing right iliac bone lesion and mesenteric nodules, suspicious for osseous and peritoneal metastases [@2022-12-29|MR].  \\n\\n- Need current whole-body FDG PET/CT to assess metabolic activity, confirm recurrence extent, and potentially upstage with additional distant lesions.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, plus pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; tumor markers (CA125, CA19-9, CA15-3) markedly elevated.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of limited/currently unclear therapeutic significance; no actionable DDR alterations documented.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial and may limit myelosuppressive therapy; renal and hepatic function currently adequate for systemic treatment.\n- Imaging suggests disseminated disease (local recurrence + peritoneal, hepatic, and osseous metastases); possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy options and line of treatment cannot be defined without confirmed primary site, histology, stage, prior treatment history, and performance status.\n- Role and timing of further local therapies (e.g., palliative RT to sacrum/presacral mass or bone lesion) vs systemic therapy-first approach are unclear.\n- Uncertain clinical significance of germline ATM variant for targeted therapies in this setting.\n\nMissing Info:\n- Definitive pathology: primary tumor type, grade, IHC, staging; any prior surgical pathology reports.\n- Full oncologic history: diagnosis date, prior systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: repeat CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation; transfusion history.\n- Any prior or recent tumor NGS/somatic profiling; prior PET/CT results, if any.\n\nWorking Plan:\n- Obtain and review complete pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Update clinical assessment: detailed symptom review (including sacral/bone pain, neurologic deficits), ECOG, and patient goals of care.\n- Repeat labs (CBC, iron studies, renal/hepatic function) and urgently address anemia (including need for transfusion) before starting/adjusting systemic therapy.\n- Consider whole-body FDG PET/CT for comprehensive staging and metabolic assessment of pelvic, liver, bone, and peritoneal disease.\n- After clarifying diagnosis, stage, prior treatments, and performance status, re-discuss in MDT to outline:  \n  - feasible systemic options (non-HRD–directed; consider clinical trials), and  \n  - palliative local measures (e.g., RT to sacrum/iliac lesion) tailored to symptoms and patient preferences.", "timestamp": "2026-01-18T18:45:30.895518"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, plus pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; tumor markers (CA125, CA19-9, CA15-3) markedly elevated.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of limited/currently unclear therapeutic significance; no actionable DDR alterations documented.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial and may limit myelosuppressive therapy; renal and hepatic function currently adequate for systemic treatment.\n- Imaging suggests disseminated disease (local recurrence + peritoneal, hepatic, and osseous metastases); possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy options and line of treatment cannot be defined without confirmed primary site, histology, stage, prior treatment history, and performance status.\n- Role and timing of further local therapies (e.g., palliative RT to sacrum/presacral mass or bone lesion) vs systemic therapy-first approach are unclear.\n- Uncertain clinical significance of germline ATM variant for targeted therapies in this setting.\n\nMissing Info:\n- Definitive pathology: primary tumor type, grade, IHC, staging; any prior surgical pathology reports.\n- Full oncologic history: diagnosis date, prior systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: repeat CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation; transfusion history.\n- Any prior or recent tumor NGS/somatic profiling; prior PET/CT results, if any.\n\nWorking Plan:\n- Obtain and review complete pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Update clinical assessment: detailed symptom review (including sacral/bone pain, neurologic deficits), ECOG, and patient goals of care.\n- Repeat labs (CBC, iron studies, renal/hepatic function) and urgently address anemia (including need for transfusion) before starting/adjusting systemic therapy.\n- Consider whole-body FDG PET/CT for comprehensive staging and metabolic assessment of pelvic, liver, bone, and peritoneal disease.\n- After clarifying diagnosis, stage, prior treatments, and performance status, re-discuss in MDT to outline:  \n  - feasible systemic options (non-HRD–directed; consider clinical trials), and  \n  - palliative local measures (e.g., RT to sacrum/iliac lesion) tailored to symptoms and patient preferences.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).", "timestamp": "2026-01-18T18:45:35.094072"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant with unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal/hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n\nControversies:\n- Systemic therapy choice and line cannot be defined without clear primary site, histology, stage, prior treatments, and performance status.\n- Unclear priority between systemic therapy and local palliative approaches (e.g., RT to sacrum/bone).\n- Uncertain clinical utility of the germline ATM variant for targeted therapies.\n\nMissing Info:\n- Definitive pathology (tumor type, grade, IHC, stage) and full prior oncology history (systemic treatments, surgery, RT, responses, toxicities).\n- Current ECOG/PS, symptom burden (pain, neurologic deficits, bleeding, systemic symptoms), and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, transfusion history.\n- Any tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Retrieve and review full pathology and historical oncology records to define diagnosis, stage, and treatment line/intent.\n- Perform updated clinical assessment (ECOG, detailed symptom review, goals of care).\n- Repeat labs and urgently address anemia (including transfusion need) before systemic treatment decisions.\n- Consider whole-body FDG PET/CT to refine staging and assess metabolic activity.\n- Re-discuss in MDT once above data available to define feasible non‑HRD systemic options (including trials) and symptom-directed local palliation (e.g., RT).\n[R1T1 DELTA] non‑gynecologic primary? | oncologist->nuclear(missing): Would a whole-body FDG PET/CT meaningfully refine staging or identify an unknown primary and additional symptomatic sites to guide systemic vs palliative local therapy planning? | pathologist->chair(missing): No surgical pathology or IHC are available to define primary site, histologic type, or grade; please obtain and upload all prior biopsy/resection reports for accurate diagnosis correlation with current imaging. | nuclear->oncologist(missing): Before systemic decisions, a whole-body FDG PET/CT would clarify metabolic activity and full extent of liver, presacral, bone, and peritoneal lesions for accurate current staging. | nuclear->radiologist(missing): Given progressive CT/MR lesions without prior PET, please consider scheduling a baseline whole-body FDG PET/CT to assess metabolic burden and detect additional occult metastases.\n[R1T2 DELTA] t load. | chair->pathologist(missing): Kindly prioritize retrieval and upload of all historical pathology/IHC reports; without a defined primary and histology, current treatment stratification remains unsafe. | chair->nuclear(safety): Agree PET/CT is valuable, but please confirm it will not delay urgent anemia workup/optimization or symptomatic local measures if needed. | oncologist->chair(missing): Given disseminated disease with severe anemia and unclear primary or line of therapy, could we prioritize obtaining prior pathology/systemic treatment records and arranging urgent labs/transfusion assessment before committing to a new systemic regimen? | oncologist->radiologist(missing): In light of nuclear’s recommendation for baseline whole-body PET/CT, can you help coordinate PET timing with potential image-guided biopsy so both staging and tissue diagnosis needs are efficiently addressed?\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, pelvic mesenteric nodules, new right iliac bone lesion, and progressive liver metastases; markedly elevated CA125/CA19‑9/CA15‑3.\n- HRD negative, BRCA1/2 wild-type; germline ATM variant of unclear therapeutic relevance; no clear actionable DDR alterations.\n- Significant anemia (Hgb ~74 g/L) likely multifactorial; renal and hepatic function currently adequate for systemic therapy.\n- Overall picture of disseminated disease; possible splenic infarct on CT.\n- Non‑gynecologic primary remains possible given lack of definitive pathology.\n\nControversies:\n- Systemic therapy choice, line of treatment, and even primary tumor site cannot be defined without prior pathology, IHC, and treatment history.\n- Priority and sequencing of systemic therapy versus local palliative measures (e.g., RT to sacrum/iliac bone) in the context of severe anemia.\n- Clinical utility of the germline ATM variant for targeted therapy remains uncertain.\n- Extent to which whole-body FDG PET/CT will change management versus adding diagnostic load in a patient with urgent anemia issues.\n\nMissing Info:\n- All historical surgical/biopsy pathology and IHC reports to define primary site, histology, and grade.\n- Full oncologic history: diagnosis date, stages, systemic regimens, surgeries, radiotherapy, responses, and toxicities.\n- Current clinical status: ECOG/PS, pain and neurologic symptoms (sacral/bone involvement), bleeding, constitutional symptoms, and patient goals/preferences.\n- Updated labs: CBC, iron studies, hemolysis markers, renal/hepatic function, coagulation, and transfusion history.\n- Any prior tumor NGS/somatic profiling and prior PET/CT, if performed.\n\nWorking Plan:\n- Urgently retrieve and upload all historical pathology/IHC and oncology treatment records to define diagnosis, primary site, stage, and line of therapy.\n- Perform updated clinical assessment (ECOG, symptom burden, neurologic exam, bleeding, goals of care).\n- Repeat labs and urgently evaluate and manage anemia (including need for transfusion) before systemic treatment decisions.\n- Coordinate a baseline whole-body FDG PET/CT to refine staging and metabolic burden, provided it does not delay anemia optimization or necessary urgent palliation.\n- Radiology and nuclear medicine to coordinate PET/CT timing with any planned image‑guided biopsy to efficiently obtain tissue and staging information.\n- Re-discuss in MDT once pathology, staging, and clinical status are clarified to define appropriate non‑HRD systemic options (including trials) and symptom‑directed local therapies (e.g., RT).", "timestamp": "2026-01-18T18:46:42.866112"}]}, "trace_events": [{"ts": "2026-01-18T18:44:36.515567", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-18T18:44:36.515717", "event": "case_fingerprint", "payload": {"case_fingerprint": "bf21a9e8fbc5"}}, {"ts": "2026-01-18T18:44:36.773658", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-18T18:44:47.560609", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-18T18:45:03.156438", "event": "rag_query", "payload": {"query": "Guidelines for management of ovarian cancer by histology and platinum sensitivity, considering extent of metastatic disease (sites unspecified) and any relevant molecular markers (e.g., BRCA/HRD/MSI/PD-L1/ATM), including options based on performance status and organ function constraints."}}, {"ts": "2026-01-18T18:45:03.156456", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-18T18:45:03.156458", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-18T18:45:03.156460", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-18T18:45:10.225683", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-18T18:45:16.644777", "event": "evidence_tag_warning", "payload": {"role": "oncologist/initial", "preview": "- Diagnosis, disease stage, prior systemic treatments, and current disease status are unknown/needs update to define treatment intent and line.    - HRD-negativ…"}}, {"ts": "2026-01-18T18:48:24.321017", "event": "mdt_discussion_end", "payload": {"merged_chars": 3486}}, {"ts": "2026-01-18T18:48:24.321858", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-18T18:48:27.983425", "event": "final_output_end", "payload": {"final_output_chars": 1306}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
